Alan B. Goldsobel

Risk of Celiac Disease Autoimmunity and Timing of Gluten Introduction in the Diet of Infants at Increased Risk of Disease

Alan B. Goldsobel · PEDIATRICS · 2006 · 349 citations

Nutrition, Food Allergy, Study Population +21

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

William W. Busse, Eugene R. Bleecker, J Mark FitzGerald et al. · The Lancet Respiratory Medicine · 2018 · 298 citations

Asthma, Rheumatology, Extension Trial +10

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

John A. Smith, Michael M. Kitt, Alyn H. Morice et al. · The Lancet Respiratory Medicine · 2020 · 216 citations · Full text

Asthma, Pulmonary Care, Phase 2B +6

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease

Joseph A. Murray, Ciarán P. Kelly, Peter H.R. Green et al. · Gastroenterology · 2016 · 131 citations · Full text

Difference Between Latiglutenase, Villous Atrophy, Clinical Presentation +3

Efficacy of doxepin in the treatment of chronic idiopathic urticaria

Alan B. Goldsobel, Albert S. Rohr, Sheldon C. Siegel et al. · Journal of Allergy and Clinical Immunology · 1986 · 98 citations

Allergy, Allergy Medicine, Medicine +5